Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 153,735 Shares of Stock

Key Points

• Ra Capital Management sold 153,735 VOR shares on April 14 at an average of $15.97 (≈$2.46M) and executed several other April disposals, totaling about $28.1 million in sales and reducing its stake by 4.51% to 3,251,263 shares (≈$51.9M).
• Vor Biopharma shares traded down 1.7% to $15.60 midday with a market cap of $762M and a 52‑week range of $2.62–$65.80, while institutional investors hold an outsized 97.29% of the stock.
• Analysts show a mixed but positive view—MarketBeat's consensus is a Moderate Buy with an average price target of $50.56, despite several recent target cuts and a range of ratings from Strong Buy to Sell.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 153,735 shares of the firm's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $15.97, for a total transaction of $2,455,147.95. Following the completion of the sale, the director owned 3,251,263 shares in the company, valued at $51,922,670.11. This represents a 4.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, April 15th, Ra Capital Management, L.P. sold 53,644 shares of Vor Biopharma stock. The stock was sold at an average price of $16.01, for a total transaction of $858,840.44.
• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The stock was sold at an average price of $15.75, for a total transaction of $13,041.00.
• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total transaction of $2,242,984.59.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The stock was sold at an average price of $16.48, for a total transaction of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The stock was sold at an average price of $18.23, for a total transaction of $4,739,800.00.

Vor Biopharma Stock Down 1.7%

NASDAQ VOR traded down $0.27 during midday trading on Wednesday, hitting $15.60. The company had a trading volume of 880,470 shares, compared to its average volume of 1,019,621. The stock has a market cap of $762.06 million, a price-to-earnings ratio of -0.04 and a beta of 1.92. The firm has a fifty day simple moving average of $14.53 and a two-hundred day simple moving average of $16.69. Vor Biopharma Inc. has a fifty-two week low of $2.62 and a fifty-two week high of $65.80.

Institutional Trading of Vor Biopharma

Several institutional investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $229,000. Susquehanna Portfolio Strategies LLC bought a new position in Vor Biopharma during the 4th quarter valued at about $134,000. Tudor Investment Corp ET AL bought a new position in Vor Biopharma during the 4th quarter valued at about $2,193,000. Sphera Funds Management LTD. bought a new position in Vor Biopharma during the 4th quarter valued at about $5,368,000. Finally, Quadrature Capital Ltd bought a new position in Vor Biopharma during the 4th quarter valued at about $350,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on VOR shares. JPMorgan Chase & Co. decreased their price target on shares of Vor Biopharma from $43.00 to $40.00 and set an "overweight" rating on the stock in a research report on Friday, December 19th. HC Wainwright decreased their target price on shares of Vor Biopharma from $32.00 to $31.00 and set a "buy" rating on the stock in a research report on Wednesday. Jefferies Financial Group initiated coverage on shares of Vor Biopharma in a research report on Monday, March 30th. They set a "buy" rating and a $50.00 target price on the stock. Citigroup initiated coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a "buy" rating and a $50.00 target price on the stock. Finally, Wedbush lifted their target price on shares of Vor Biopharma to $15.00 and gave the company a "neutral" rating in a research report on Tuesday, March 31st. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $50.56.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.